Downloadable Slides From Integrating New Treatments for HER2+ Early Breast Cancer: Time for a Risk-Adapted Approach
After successful completion of this educational activity, participants should be able to:
- Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
- Select the optimum HER2-targeted strategy and duration of treatment to improve long-term disease endpoints in patients with HER2+ early breast cancer
- Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
- Understand the limitations of health care funding for HER2+ early breast cancer and the need for a risk-adapted strategy
Enhance your understanding of optimal treatment approaches for HER2+ early breast cancer with these prIME Oncology downloadable slides. A variety of therapeutic strategies are covered, including short duration regimens, extended adjuvant therapy, dual HER2 blockade, and patient selection for these strategies. Optimizing the risk-benefit profile of different regimens is also addressed, with information on prevention and management of adverse events. Finally, emerging agents and potential future opportunities provided by new HER2-targeted strategies that address areas of continuing unmet clinical need are covered.
This activity is provided by prIME Oncology.
This educational activity is supported by a grant from Puma Biotechnology.
- Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Center for Hematology and Oncology Bethanien, Frankfurt, Germany
The case for dual blockade
- Michael Untch, MD, PhD, HELIOS Klinikum Berlin-Buch, Berlin, Germany
The case for extended adjuvant treatment
- Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France
The case for reduced treatment
- Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany
Optimizing the risks and benefits of treatment
- Suzette Delaloge, MD, MSc, Gustave Roussy, Villejuif, France
Borrowing from Maria to treat Sophia: A risk-adapted approach to treatment
- Cristina Saura, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain
Emerging treatments for HER2+ and mutant breast cancer
- Hope S. Rugo, MD, FACP, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States